Development Programs

Research Pipeline

Four development programs targeting neuroprotection across distinct at-risk populations. All based on the same core lipid supplementation platform.

Home/Pipeline

Development Phases

Discovery

Mechanism characterization, lipid target identification, biomarker development

Preclinical

In vitro and in vivo safety, efficacy, and biomarker validation studies

Phase I

First-in-human safety, tolerability, and PK/PD studies in healthy volunteers

Phase II

Proof-of-concept efficacy in target populations with biomarker endpoints

Phase III

Pivotal efficacy and safety trials for regulatory approval

Development Programs

NS-001PreclinicalActiveOral lipid supplement

Blast TBI Prevention in Warfighters

NS-001 targets modification of neuronal membrane DHA and plasmalogen content in military personnel at sustained blast exposure risk. Preclinical models demonstrate reduced neuroinflammatory response and preserved cognitive performance following simulated blast events in supplemented animals.

Target Populations

  • Active duty military
  • Combat-exposed personnel

Current Milestone

IND-enabling studies in progress

NS-002PreclinicalActiveOral lipid supplement

Cumulative Impact Neuroprotection in Contact Athletes

NS-002 is designed for the contact sport athlete population, targeting the subconcussive impact accumulation that precedes detectable clinical injury. Rodent repetitive impact models show significant reduction in white matter injury markers and behavioral deficits in treated animals.

Target Populations

  • Professional contact sport athletes
  • Collegiate athletes

Current Milestone

Dose-response characterization ongoing

NS-003DiscoveryOral lipid supplement

Age-Associated Membrane Decline and Fall-Related TBI

NS-003 addresses the natural decline in neuronal membrane plasmalogen content with aging, which substantially increases vulnerability to injury from falls and minor head trauma. Discovery work is characterizing the lipid deficiency profile across age cohorts to identify optimal supplementation targets.

Target Populations

  • Adults 65+
  • Assisted living populations

Current Milestone

Lipid profiling studies underway

NS-004DiscoveryOral lipid supplement

First Responder Occupational Neurological Risk

NS-004 addresses cumulative neurological burden in first responders from blast exposure (firefighting), repeated physical trauma, and toxic environmental exposures. Epidemiological work is characterizing biomarker burden in active first responders to inform membrane-targeted intervention design.

Target Populations

  • Firefighters
  • Law enforcement
  • Emergency medical personnel

Current Milestone

Epidemiological study design phase

Platform Approach

All four NeuroShield Sciences programs are built on the same foundational platform: oral lipid supplementation that modifies neuronal plasma membrane composition through established lipid transport pathways. This platform approach means that efficacy demonstrated in one population generates meaningful evidence for the others, and manufacturing, regulatory, and clinical development capabilities are shared across the pipeline.

The modality (oral supplement) is well-tolerated, scalable, and appropriate for the prophylactic use case: protecting individuals before injury occurs, not treating them after.

Collaborate on Our Pipeline

We are actively seeking clinical site partners, academic collaborators, and strategic partners across all four programs.

Contact Us
Built with Founden.ai